Prous Institute Presents the 10th edition of the Prous Institute – Overton & Meyer Award for New Technologies in Drug Discovery to Prof. Alessio Ciulli
Prous Institute for Biomedical Research is to present the 2022 Prous Institute – Overton & Meyer Award to Professor Alessio Ciulli, at the XXVII International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC).
The award, conferred every two years since 2004 and now in its tenth edition, recognizes outstanding contributions to the development of new technologies in the field of medicinal chemistry and acknowledges the awardee’s contribution to the discovery and development of innovative technologies that advance the field.
Prof. Ciulli has pioneered the field of targeted protein degradation (TPD) as a new therapeutic modality. A major highlight of his contributions is the discovery of proteolysis-targeting chimera or PROTAC and its potential application in the fields of cancer, Parkinson’s and other diseases.
Prof. Ciulli is Professor of Chemical & Structural Biology at the School of Life Sciences, University of Dundee, when he founded and directs the Dundee new Centre for Targeted Protein Degradation. He is also the scientific co-founder and advisor of Amphista Therapeutics.
The award will be presented during the XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022), to be held in Nice, France, on September 4 – September 8, 2022. The Award plenary Lecture is scheduled for Tuesday, September 6 at 08:30 a.m. CET.
About the Prous Institute for Biomedical Research
Prous Institute for Biomedical Research, created as a spin-off of Prous Science (acquired by Thomson Reuters, now Clarivate Analytics, in 2007) is committed to supporting the discovery of novel therapeutic and diagnostic approaches.
Originally founded by Dr. J.R. Prous, Prous Institute has evolved to expand its mission beyond its own developments by partnering and investing in transformative science initiatives.
By leveraging more than 60 years’ experience in the life sciences, we offer the resources and capabilities needed by researchers to move their research closer to the patient bedside.
About the European Federation of Medicinal Chemistry (EFMC)
The EFMC is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.